# ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

Source: https://onco.cc/trials/nct04205227/  
OnCo record `nct04205227` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in melanoma, run by ENB Therapeutics, Inc, active and no longer recruiting.

## Summary

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors is a phase 1/2 interventional study registered as NCT04205227 by ENB Therapeutics, Inc, with 137 participants planned, started 2020-02-18 and due to reach its primary completion in 2026-01-01. Interventions recorded: ENB003, Pembrolizumab. Conditions listed: Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04205227
- Phase: 1/2
- Setting: A Phase 1/2A Trial of ENB 003 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
- Sponsor: ENB Therapeutics, Inc
- Enrolled: 137

## Sources

- ClinicalTrials.gov NCT04205227: https://clinicaltrials.gov/study/NCT04205227

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [ENB003](https://onco.cc/drugs/enb003/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct04205227.json